ArticleCurrent oncology (Toronto, Ont.)2016

Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.

J Amdahl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.